Aptahem (publ) announces today that the company has signed an agreement to initiate activities (Start Up Agreement, SUA) with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to prepare the upcoming...
Read MoreAptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been published with patent number 3691655. With these...
Read MoreBioStock published an article on 2 December 2021 about Aptahem, which can be read in full below. Aptahem’s collaboration with Örebro University recently led to a research breakthrough regarding a newfound pharmacological mechanism behind Aptahem’s sepsis treatment Apta-1. BioStock...
Read MoreAptahem can today announce that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 has started at the collaboration partner LGC Biotechnologies’ facilities in the USA, with planned delivery date in early 2022. The GMP...
Read MoreAptahem can today announce that in a Corona virus challenge induced Acute Lung Injury model studies with Apta-1 treatment shows strong evidence in maintaining systemic circulation, protection of vital organs, regulation of crucial cytokines and preventing hemolysis. Research commissioned...
Read MoreIt is time for 2021’s edition of the largest partnering meeting in the life science space – BIO-Europe. This week, representatives from nearly 1,500 companies will gather to establish new contacts as well as continue initiated discussions with potential...
Read MoreOn Thursday 21 October 2021 at 11.40 CET, CEO Mikael Lindstam will present the latest development in Aptahem and the lead candidate Apta-1 at the BioStock Life Science Summit. The event can be followed online via the link: BioStock...
Read MoreAptahem AB (publ) announces today that the Turkish patent office has approved the patent application as the first validated country in Europe. The patent was published with the patent number TR2021/013877 T4. The approval by the Turkish patent office...
Read MoreAptahem AB develops drugs for the treatment of acute life-threatening conditions where Apta-1, the company’s main candidate, is under development and intended as an emergency drug to prevent the occurrence of organ and tissue damage in patients suffering from...
Read MoreAptahem can today announce that further studies with Örebro University on Apta-1 show strong evidence in its features on the coagulation and inflammation by a unique modulation of Thrombin. This mechanism of action distinctly differs from current clinical used...
Read More